← Human Trials & Peer-Reviewed Studies
Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome
Plain-language guide to NCT07460908: not phased randomized trial of Octreotide and Terlipressin, 60 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07460908
- Phase
- not phased
- Status
- completed
- Start
- 2025-05-01
- Completion (planned or actual)
- 2025-10-30
- Participants
- 60 (actual)
- Design
- randomized, single-blind, treatment
- Conditions studied
- Hepatorenal Syndrome
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this not phased trial, researchers set out to test Octreotide and Terlipressin.
Hepatorenal syndrome is a serious complication of advanced liver disease in which kidney function rapidly worsens and can lead to life-threatening illness.
It had two arms (groups): Group Terlipressin (experimental) and Group Octreotide (active comparator).
Participants will receive terlipressin as per study protocol for the treatment of hepatorenal syndrome.
Participants will receive octreotide as per study protocol for the treatment of hepatorenal syndrome.
The registry classes the interventions as drug.
Who Took Part
Enrollment: 60 actual participants took part.
It was open to people of any sex aged from 30 years up to 70 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Age 30 to 70 years. Diagnosed with hepatorenal syndrome.
The full record lists 3 inclusion and 6 exclusion criteria; among the exclusions: hepatocellular carcinoma; septic shock; cardiac failure.
How the Study Was Run
Design: randomized, parallel-group and single-blind.
Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The Octreotide group and the comparison group ran side by side rather than switching.
Only one side, usually the participants, was kept unaware of whether Octreotide was given.
Those kept unaware of assignments: participant.
It started in 2025-05-01 with completion listed for 2025-10-30.
It ran at 1 site in Pakistan.
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Treatment response based on serum creatinine at 48 hours (time frame: Baseline and 48 hours after initiation of treatment).
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of Octreotide and Terlipressin in 60 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Octreotide compound page and the Terlipressin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Terlipressin: A synthetic vasopressin analog (Terlivaz) used for kidney failure in advanced liver disease and for variceal bleeding.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.